All lobbying filings

THE MCMANUS GROUP

Lobbying for ALNYLAM PHARMACEUTICALS · Biopharmaceutical company

Filing 3rd Quarter - Termination

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 20, 2025

Income

$20,000.00

What the client paid this registrant for the period.

Client based in

Massachusetts

Representation ended

Jul 31, 2025

The registrant reported terminating its work for this client.

Official filing document

Lobbyists on this filing 1

JOHN MCMANUS

Previously held: Staff Director W&M Health Subcommittee; LA, Rep. Bill Thomas

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 1

HR 1672
Maintaining Investments in New Innovation Act

Lobbying activity 1

Medicare/Medicaid

Support for H.R. 1672 - Maintaining Investments in New Innovation Act Issues related to access and coverage in Medicare program. Implementation of provisions included in Subtitle B of PL. 117-169-Infation Reduction Act of 2022

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.